NO20070324L - Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnere - Google Patents
Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnereInfo
- Publication number
- NO20070324L NO20070324L NO20070324A NO20070324A NO20070324L NO 20070324 L NO20070324 L NO 20070324L NO 20070324 A NO20070324 A NO 20070324A NO 20070324 A NO20070324 A NO 20070324A NO 20070324 L NO20070324 L NO 20070324L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- methods
- binding partners
- bcl proteins
- inhibiting bcl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Det beskrives isoksazolinderivater som binder til Bcl-proteiner og inhiberer Bcl-funksjon. Et annet aspekt angår preparater omfattende et isoksazolinderivat som beskrevet. Videre tilveiebringes metoder for behandling og modulering av forstyrrelser assosiert med hyperproliferering, for eksempel cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58061604P | 2004-06-17 | 2004-06-17 | |
US65930105P | 2005-03-07 | 2005-03-07 | |
PCT/US2005/021524 WO2006009869A1 (en) | 2004-06-17 | 2005-06-17 | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070324L true NO20070324L (no) | 2007-03-19 |
Family
ID=35335774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070324A NO20070324L (no) | 2004-06-17 | 2007-01-17 | Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnere |
Country Status (22)
Country | Link |
---|---|
US (1) | US7851637B2 (no) |
EP (1) | EP1768966B1 (no) |
JP (1) | JP5064213B2 (no) |
KR (1) | KR101195351B1 (no) |
CN (1) | CN101006065B (no) |
AT (1) | ATE548359T1 (no) |
AU (1) | AU2005265131B2 (no) |
BR (1) | BRPI0511070A (no) |
CA (1) | CA2570780C (no) |
EC (1) | ECSP067099A (no) |
ES (1) | ES2382383T3 (no) |
HK (1) | HK1105963A1 (no) |
IL (1) | IL179904A (no) |
MA (1) | MA28702B1 (no) |
MX (1) | MXPA06014754A (no) |
NO (1) | NO20070324L (no) |
NZ (1) | NZ552183A (no) |
PL (1) | PL1768966T3 (no) |
PT (1) | PT1768966E (no) |
RU (1) | RU2416606C2 (no) |
WO (1) | WO2006009869A1 (no) |
ZA (1) | ZA200610405B (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
BRPI0511070A (pt) | 2004-06-17 | 2007-11-27 | Infinity Pharmaceuticals Inc | compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação |
US8624027B2 (en) * | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
EP1897956A1 (en) | 2006-09-06 | 2008-03-12 | Lonza AG | Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase |
BRPI0907754A2 (pt) * | 2008-02-08 | 2015-07-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos terapêuticos |
WO2009158011A1 (en) * | 2008-06-26 | 2009-12-30 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
WO2010021752A1 (en) * | 2008-08-21 | 2010-02-25 | Alvine Pharmaceuticals, Inc. | Formulation for oral administration of proteins |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
MX2011005922A (es) * | 2008-12-05 | 2011-06-16 | Abbott Lab | Derivados de sulfonamida como agentes inductores de apoptosis selectiva de bcl-2 para el tratamiento del cancer y enfermedades inmunes. |
TWI537269B (zh) * | 2009-05-26 | 2016-06-11 | 艾伯維巴哈馬有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑 |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US10709692B2 (en) * | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
CA3103604C (en) | 2016-03-28 | 2023-09-26 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
US20230270816A1 (en) | 2020-07-06 | 2023-08-31 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
JPS55133364A (en) * | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
DE3643012A1 (de) * | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
DE3829594A1 (de) * | 1988-09-01 | 1990-03-15 | Bayer Ag | Neue renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
DE3926822A1 (de) * | 1989-08-14 | 1991-02-21 | Hoechst Ag | Peptide mit bradykinin-antagonistischer wirkung |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5494911A (en) | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
HUT74690A (en) * | 1993-11-24 | 1997-01-28 | Du Pont Merck Pharma | Novel isoxazoline and isoxazole fibrinogen receptor antagonists process for producing them and pharmaceutical compositions containing them |
ATE187447T1 (de) * | 1993-11-26 | 1999-12-15 | Pfizer | 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel |
WO1995024398A1 (en) | 1994-03-09 | 1995-09-14 | Pfizer Inc. | Isoxazoline compounds as inhibitors of tnf release |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
US6221865B1 (en) * | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
IT1283836B1 (it) | 1996-08-28 | 1998-04-30 | Viv Int Spa | Procedimento per decorare profilati metallici,in materiale plastico e simili e relativa apparecchiatura |
WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
WO1998050030A1 (en) * | 1997-05-07 | 1998-11-12 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
WO2001016115A1 (en) | 1999-09-01 | 2001-03-08 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
DE60237115D1 (de) | 2001-05-30 | 2010-09-02 | Univ Georgetown | Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs. |
US20030119894A1 (en) | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
BRPI0511070A (pt) | 2004-06-17 | 2007-11-27 | Infinity Pharmaceuticals Inc | compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação |
-
2005
- 2005-06-17 BR BRPI0511070-0A patent/BRPI0511070A/pt active Search and Examination
- 2005-06-17 KR KR1020077001087A patent/KR101195351B1/ko not_active IP Right Cessation
- 2005-06-17 PT PT05762701T patent/PT1768966E/pt unknown
- 2005-06-17 RU RU2007101276/04A patent/RU2416606C2/ru not_active IP Right Cessation
- 2005-06-17 WO PCT/US2005/021524 patent/WO2006009869A1/en active Application Filing
- 2005-06-17 JP JP2007516793A patent/JP5064213B2/ja not_active Expired - Fee Related
- 2005-06-17 AT AT05762701T patent/ATE548359T1/de active
- 2005-06-17 NZ NZ552183A patent/NZ552183A/en not_active IP Right Cessation
- 2005-06-17 AU AU2005265131A patent/AU2005265131B2/en not_active Ceased
- 2005-06-17 CA CA2570780A patent/CA2570780C/en not_active Expired - Fee Related
- 2005-06-17 PL PL05762701T patent/PL1768966T3/pl unknown
- 2005-06-17 ES ES05762701T patent/ES2382383T3/es active Active
- 2005-06-17 US US11/156,364 patent/US7851637B2/en not_active Expired - Fee Related
- 2005-06-17 CN CN2005800281288A patent/CN101006065B/zh not_active Expired - Fee Related
- 2005-06-17 EP EP05762701A patent/EP1768966B1/en active Active
- 2005-06-17 MX MXPA06014754A patent/MXPA06014754A/es active IP Right Grant
-
2006
- 2006-12-07 IL IL179904A patent/IL179904A/en not_active IP Right Cessation
- 2006-12-12 ZA ZA200610405A patent/ZA200610405B/en unknown
- 2006-12-20 EC EC2006007099A patent/ECSP067099A/es unknown
- 2006-12-29 MA MA29588A patent/MA28702B1/fr unknown
-
2007
- 2007-01-17 NO NO20070324A patent/NO20070324L/no not_active Application Discontinuation
- 2007-10-17 HK HK07111188.2A patent/HK1105963A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2416606C2 (ru) | 2011-04-20 |
AU2005265131A1 (en) | 2006-01-26 |
MXPA06014754A (es) | 2007-06-22 |
CN101006065A (zh) | 2007-07-25 |
ES2382383T3 (es) | 2012-06-07 |
MA28702B1 (fr) | 2007-06-01 |
PT1768966E (pt) | 2012-05-23 |
JP2008503489A (ja) | 2008-02-07 |
CN101006065B (zh) | 2012-07-11 |
CA2570780A1 (en) | 2006-01-26 |
BRPI0511070A (pt) | 2007-11-27 |
WO2006009869A1 (en) | 2006-01-26 |
ATE548359T1 (de) | 2012-03-15 |
JP5064213B2 (ja) | 2012-10-31 |
HK1105963A1 (en) | 2008-02-29 |
ECSP067099A (es) | 2007-04-26 |
NZ552183A (en) | 2009-10-30 |
EP1768966B1 (en) | 2012-03-07 |
US7851637B2 (en) | 2010-12-14 |
IL179904A0 (en) | 2007-05-15 |
KR101195351B1 (ko) | 2012-10-29 |
IL179904A (en) | 2011-11-30 |
PL1768966T3 (pl) | 2012-08-31 |
CA2570780C (en) | 2013-12-03 |
KR20070046068A (ko) | 2007-05-02 |
RU2007101276A (ru) | 2008-08-10 |
US20060025460A1 (en) | 2006-02-02 |
EP1768966A1 (en) | 2007-04-04 |
AU2005265131B2 (en) | 2012-02-23 |
ZA200610405B (en) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070324L (no) | Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnere | |
MX2009005184A (es) | Compuestos y metodos para inhibir la interaccion de las proteinas bcl con agentes aglutinantes. | |
NO20091213L (no) | Forbindelser og fremgangsmater for a inhibere interaksjoner mellom BCL proteiner og bindingspartnere | |
MY153232A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
ATE554087T1 (de) | Neue kinaseinhibitoren | |
TW200602029A (en) | Inhibitors of IAP | |
TW200640924A (en) | VEGF-R2 inhibitors and methods | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
DK1836169T5 (da) | Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser | |
TW200716624A (en) | Compounds for modulating TRPV3 function | |
EA200800374A1 (ru) | 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции | |
WO2007022947A3 (de) | 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren | |
EA201270630A1 (ru) | Гетероциклические сетр ингибиторы | |
WO2007022241A3 (en) | Novel high affinity quinoline-based kinase ligands | |
WO2003084475A3 (en) | INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME | |
ATE443044T1 (de) | Tace inhibitoren | |
WO2004058705A3 (en) | Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor | |
WO2004060878A3 (en) | Inhibitors of phosphatases | |
TNSN06418A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
MY155908A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
DK1730196T3 (da) | EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst | |
MY143200A (en) | Monocyclic heterocycles as kinase inhibitors | |
CY1115478T1 (el) | Ενωσεις τριαζολης που διαμορφωνουν δραση ηsρ90 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |